Volume 17, Issue 1 (March-2025 2025)                   Iranian Journal of Blood and Cancer 2025, 17(1): 71-90 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Razani E, Maryam Khiabani Rad M, Larki Tork E, Bahmani F. Investigating the Refractory Platelet Transfusion: Understanding the Underlying Factors, Diagnosis, and Effective Treatment Strategies. Iranian Journal of Blood and Cancer 2025; 17 (1) :71-90
URL: http://ijbc.ir/article-1-1669-en.html
Investigating the Refractory Platelet Transfusion: Understanding the Underlying Factors, Diagnosis, and Effective Treatment Strategies
Elham Razani *1 , Maryam Maryam Khiabani Rad2 , Ehsan Larki Tork3 , Fourozan Bahmani4
1- Department of Hematology and Transfusion Sciences, School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran , Elham.razani.mls@gmail.com
2- Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3- Department of Hematology and Transfusion Sciences, School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran
4- Abadan Faculty of medical sciences, Abadan, Iran 4- Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Abstract:   (713 Views)
This review article provides a comprehensive overview of platelet transfusion-refractory (PTR), a condition in which patients do not respond well to platelet transfusions, leading to increased bleeding and complications. It discusses various aspects of PTR such as its causes, prevention, diagnosis, management, and potential complications. While immune-mediated reactions are the primary cause, non-immunologic, patient-related, and donor-related factors can also contribute. Preventing PTR involves methods such as HLA matching, platelet count monitoring, and prophylactic transfusions; however, alternative approaches require further research. Accurate diagnosis is crucial, with treatment strategies depending on the cause often requiring platelet transfusions from HLA-matched donors or immunosuppressive therapies. Complications included bleeding, infection, and adverse drug reactions, highlighting the need for proper management and monitoring. Future research should focus on patient-specific risk factors, alternative prevention methods, and blood product safety. Understanding immune-mediated reactions and other causes, prevention, diagnosis, management, and potential complications can improve outcomes in patients needing platelet transfusions. In conclusion, PTR is a complex condition that healthcare professionals must handle carefully. Ongoing research is crucial to advancing knowledge, enhancing care, and improving patient outcomes.
Keywords: Platelet, Platelet immunology, Transfusion medicine, Platelet transfusion refractory
Full-Text [PDF 648 kb]   (544 Downloads)    
: Review Article | Subject: Immunology
Received: 2025/01/2 | Accepted: 2025/03/26 | Published: 2025/03/30
References
1. Friedman MT, Avadhani V, Gilmore S, Madrigal E. Blood transfusion in the 21st century. Discoveries. 2014;2(1). [DOI:10.15190/d.2014.3]
2. Rebulla P. Platelet transfusion therapy: hot topics in 2021. Annals of Blood. 2022;7. [DOI:10.21037/aob-21-56]
3. Wandt H, Schaefer-Eckart K, Wendelin K, Pilz B, Wilhelm M, Thalheimer M, et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet. 2012;380(9850):1309-16. [DOI:10.1016/S0140-6736(12)60689-8]
4. Nahirniak S, Slichter SJ, Tanael S, Rebulla P, Pavenski K, Vassallo R, et al. Guidance on platelet transfusion for patients with hypoproliferative thrombocytopenia. Transfusion medicine reviews. 2015;29(1):3-13. [DOI:10.1016/j.tmrv.2014.11.004]
5. Perrotta P, Snyder E. Non-infectious complications of transfusion therapy. Blood reviews. 2001;15(2):69-83. [DOI:10.1054/blre.2001.0151]
6. Sharma S, Joshi PK, Bundas S, Sharma A. Effect of Donor and Patient Variables on the Platelet Increment and Percent Platelet Recovery: Experience from Tertiary Care Center in North-Western India. Global Journal of Transfusion Medicine. 2022;7(2):196-200. [DOI:10.4103/gjtm.gjtm_37_22]
7. Modery-Pawlowski CL, Tian LL, Pan V, McCrae KR, Mitragotri S, Gupta AS. Approaches to synthetic platelet analogs. Biomaterials. 2013;34(2):526-41. [DOI:10.1016/j.biomaterials.2012.09.074]
8. Schwartz J, Padmanabhan A, Aqui N, Balogun RA, Connelly‐Smith L, Delaney M, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence‐based approach from the writing committee of the American society for apheresis: the seventh special issue. Journal of clinical apheresis. 2016;31(3):149-338. https://doi.org/10.1002/jca.21470 [DOI:10.1002/jca.21470_c]
9. Forest SK, Hod EA. Management of the platelet refractory patient. Hematology/Oncology Clinics. 2016;30(3):665-77. [DOI:10.1016/j.hoc.2016.01.008]
10. Levin J, Bessman JD. The inverse relation between platelet volume and platelet number: abnormalities in hematologic disease and evidence that platelet size does not correlate with platelet age. The Journal of laboratory and clinical medicine. 1983;101(2):295-307.
11. Novotny V. Prevention and management of platelet transfusion refractoriness. Vox Sanguinis. 1999;76(1):1-13. [DOI:10.1046/j.1423-0410.1999.7610001.x]
12. Hanson SR, Slichter SJ. Platelet kinetics in patients with bone marrow hypoplasia: evidence for a fixed platelet requirement. Blood. 1985;66(5):1105-9. https://doi.org/10.1182/blood.V66.5.1105.bloodjournal6651105 [DOI:10.1182/blood.V66.5.1105.1105]
13. Estcourt L, Birchall J, Lowe D, Grant‐Casey J, Rowley M, Murphy M. Platelet transfusions in haematology patients: are we using them appropriately? Vox sanguinis. 2012;103(4):284-93. [DOI:10.1111/j.1423-0410.2012.01627.x]
14. Das N, Prakash S, Sahu A, Panigrahi A, Mishra D, Mukherjee S. Impact of dose and storage duration of platelet concentrates on platelet recovery between ABO identical and ABO non-identical random donor platelet transfusions in hemato-oncology patients. Hematology, Transfusion and Cell Therapy. 2024;46:228-36. [DOI:10.1016/j.htct.2023.01.011]
15. Chen L, Zhou H, Guo B, Guan Z. Clinical efficacy of platelet transfusion therapy in patients with leukemia and analysis of risk factors for ineffective transfusion. Oncology Letters. 2020;19(3):2554-61. [DOI:10.3892/ol.2020.11268]
16. Tormey CA, Hendrickson JE. Platelet transfusion refractory patients. Transfusion Medicine and Hemostasis: Elsevier; 2019. p. 361-4. [DOI:10.1016/B978-0-12-813726-0.00057-X]
17. Lee ML. of nonimmune-mediated platelet destruction following these test trans. Intravenous Immunoglobulins in Clinical Practice: CRC Press; 1997. p. 344-6. [DOI:10.1201/9781420001143-60]
18. Slichter SJ. Evidence-based platelet transfusion guidelines. ASH Education Program Book. 2007;2007(1):172-8. [DOI:10.1182/asheducation-2007.1.172]
19. Sijimol Mathew M. Platelet Refractoriness. Clinical Journal of Oncology Nursing. 2021;25(1):89-93. [DOI:10.1188/21.CJON.89-92]
20. Mathew S. Platelet Refractoriness: Examining associated morbidity and mortality. Clinical Journal of Oncology Nursing. 2021;25(1). [DOI:10.1188/21.CJON.89-92]
21. Chellaiya GK, Nair CK, Raghavan V, Pandian RJ, Vinod R, Murugesan M. Extent of transfusion support in a developing country in managing a bleeding acute myeloid leukemia patient with platelet transfusion refractoriness. Asian Journal of Transfusion Science. 2021;15(1):90-3. [DOI:10.4103/ajts.AJTS_81_19]
22. Murphy M. Managing the platelet refractory patient. ISBT Science Series. 2014;9(1):234-8. [DOI:10.1111/voxs.12073]
23. Chammard TB, Schepers K, Breurec S, Messiaen T, Destrem A-L, Mahevas M, et al. Severe thrombocytopenia after Zika virus infection, Guadeloupe, 2016. Emerging Infectious Diseases. 2017;23(4):696. [DOI:10.3201/eid2304.161967]
24. Zarychanski R, Abou-Setta AM, Turgeon AF, Houston BL, McIntyre L, Marshall JC, et al. Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: a systematic review and meta-analysis. Jama. 2013;309(7):678-88. [DOI:10.1001/jama.2013.430]
25. Warkentin TE, Sheppard J-AI, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood, The Journal of the American Society of Hematology. 2000;96(5):1703-8. .h8001703_1703_1708 [DOI:10.1182/blood.V96.5.1703]
26. Nguyen HB, Rivers EP, Abrahamian FM, Moran GJ, Abraham E, Trzeciak S, et al. Severe sepsis and septic shock: review of the literature and emergency department management guidelines. Annals of emergency medicine. 2006;48(1):54. e1. [DOI:10.1016/j.annemergmed.2006.02.015]
27. Warkentin TE, Greinacher A. Laboratory testing for heparin-induced thrombocytopenia. Heparin-Induced Thrombocytopenia 3rd ed New York, NY: Marcel Dekker. 2004:271-311. [DOI:10.1378/chest.126.3_suppl.311S]
28. Warkentin T, Greinacher A, Gruel Y, Aster R, Chong B. Laboratory testing for heparin‐induced thrombocytopenia: a conceptual framework and implications for diagnosis. Journal of Thrombosis and Haemostasis. 2011;9(12):2498-500. [DOI:10.1111/j.1538-7836.2011.04536.x]
29. Kiefel V, Santoso S, Weisheit M, Mueller-Eckhardt C. Monoclonal antibody--specific immobilization of platelet antigens (MAIPA): a new tool for the identification of platelet-reactive antibodies. 1987. [DOI:10.1182/blood.V70.6.1722.bloodjournal7061722]
30. Shah S, Sweeney R, Rai M, Shah D. A Case of vancomycin-induced severe immune thrombocytopenia. Hematology Reports. 2023;15(2):283-9. [DOI:10.3390/hematolrep15020028]
31. Arnold DM, Nazi I, Warkentin TE, Smith JW, Toltl LJ, George JN, et al. Approach to the diagnosis and management of drug-induced immune thrombocytopenia. Transfusion medicine reviews. 2013;27(3):137-45. [DOI:10.1016/j.tmrv.2013.05.005]
32. Aster RH, Curtis BR, McFarland JG, Bougie DW. Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management. Journal of Thrombosis and Haemostasis. 2009;7(6):911-8. [DOI:10.1111/j.1538-7836.2009.03360.x]
33. Levi M, Toh C, Thachil J, Watson H. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British journal of haematology. 2009;145(1):24-33. [DOI:10.1111/j.1365-2141.2009.07600.x]
34. Gresele P, Harrison P, Bury L, Falcinelli E, Gachet C, Hayward C, et al. Diagnosis of suspected inherited platelet function disorders: results of a worldwide survey. Journal of Thrombosis and Haemostasis. 2014;12(9):1562-9. [DOI:10.1111/jth.12650]
35. Perrotta PL, Snyder EL. Non-infectious complications of transfusion therapy. Blood Rev. 2001;15(2):69-83. [DOI:10.1054/blre.2001.0151]
36. Stroncek DF, Rebulla P. Platelet transfusions. The Lancet. 2007;370(9585):427-38. [DOI:10.1016/S0140-6736(07)61198-2]
37. Group TtRAtPS. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. New England Journal of Medicine. 1997;337(26):1861-70. [DOI:10.1056/NEJM199712253372601]
38. Bolliger D, Görlinger K, Tanaka KA, Warner DS. Pathophysiology and treatment of coagulopathy in massive hemorrhage and hemodilution. The Journal of the American Society of Anesthesiologists. 2010;113(5):1205-19. [DOI:10.1097/ALN.0b013e3181f22b5a]
39. Woodman RC, Harker LA. Bleeding complications associated with cardiopulmonary bypass. 1990. [DOI:10.1182/blood.V76.9.1680.1680]
40. Fraga GP, Bansal V, Coimbra R. Transfusion of blood products in trauma: an update. The Journal of emergency medicine. 2010;39(2):253-60. [DOI:10.1016/j.jemermed.2009.02.034]
41. Fletcher CH, DomBourian MG, Millward PA. Platelet transfusion for patients with cancer. Cancer Control. 2015;22(1):47-51. [DOI:10.1177/107327481502200107]
42. Cohn CS. Platelet transfusion refractoriness: how do I diagnose and manage? Hematology 2014, the American Society of Hematology Education Program Book. 2020;2020(1):527-32. [DOI:10.1182/hematology.2020000137]
43. Okolo R, Ufelle S, Ogbuabor A, Peter U, Achukwu P. The Human Platelet and Leucocyte Antigens: Locations, Diagnosis and Solutions. J Blood Lymph. 2019;9(252):2.
44. Kreuger AL, Mäkelburg AB, Somers JA, Tomson B, van de Watering LM, van der Bom JG, et al. HLA‐matched platelet transfusions are effective only in refractory patients with positive HLA antibody screening. Transfusion. 2019;59(11):3303-7. [DOI:10.1111/trf.15530]
45. Rioux‐Massé B, Cohn C, Lindgren B, Pulkrabek S, McCullough J. Utilization of cross‐matched or HLA‐matched platelets for patients refractory to platelet transfusion. Transfusion. 2014;54(12):3080-7. [DOI:10.1111/trf.12739]
46. Novotný VM, Doxiadis II, Brand A. The reduction of HLA class I expression on platelets: a potential approach in the management of HLA-alloimmunized refractory patients. Transfusion medicine reviews. 1999;13(2):95-105. [DOI:10.1016/S0887-7963(99)80004-2]
47. Valentin N, Vergracht A, Bignon J, Cheneau M, Blanchard D, Kaplan C, et al. HLA-DRw52a is involved in alloimmunization against PL-A1 antigen. Human immunology. 1990;27(2):73-9. [DOI:10.1016/0198-8859(90)90104-W]
48. Ogasawara K, Ueki J, Takenaka M, Furihata K. Study on the expression of ABH antigens on platelets. 1993. [DOI:10.1182/blood.V82.3.993.993]
49. Curtis BR, Edwards JT, Hessner MJ, Klein JP, Aster RH. Blood group A and B antigens are strongly expressed on platelets of some individuals. Blood, The Journal of the American Society of Hematology. 2000;96(4):1574-81. .h8001574_1574_1581 [DOI:10.1182/blood.V96.4.1574]
50. Heal JM, Blumberg N, Masel D. An evaluation of crossmatching, HLA, and ABO matching for platelet transfusions to refractory patients. 1987. [DOI:10.1182/blood.V70.1.23.bloodjournal70123]
51. Dunbar NM. Does ABO and RhD matching matter for platelet transfusion? Hematology 2014, the American Society of Hematology Education Program Book. 2020;2020(1):512-7. [DOI:10.1182/hematology.2020000135]
52. Eisenberg S. Refractory response to platelet transfusion therapy. Journal of Infusion Nursing. 2010;33(2):89-97. [DOI:10.1097/NAN.0b013e3181cfd392]
53. Dzik WH, Murphy MF. Introduction: Two Centuries of Progress in Transfusion Medicine. Practical Transfusion Medicine. 2022:1-10. [DOI:10.1002/9781119665885.ch1]
54. Chockalingam P, Sacher RA. Management of patients refractory to platelet transfusion. Journal of Infusion Nursing. 2007;30(4):220-5. [DOI:10.1097/01.NAN.0000281531.97183.c0]
55. Agarwal N, Chatterjee K, Sen A, Kumar P. Prevalence of platelet reactive antibodies in patient's refractory to platelet transfusions. Asian journal of transfusion science. 2014;8(2):126-7. [DOI:10.4103/0973-6247.137453]
56. Hendrickson JE, Roback JD. Platelet transfusion refractory patients. Transfusion Medicine and Hemostasis: Elsevier; 2009. p. 283-6. [DOI:10.1016/B978-0-12-374432-6.00049-X]
57. Aster RH, Bougie DW. Drug-induced immune thrombocytopenia. New England Journal of Medicine. 2007;357(6):580-7. [DOI:10.1056/NEJMra066469]
58. Kimmoun A, Oulehri W, Sonneville R, Grisot P-H, Zogheib E, Amour J, et al. Prevalence and outcome of heparin-induced thrombocytopenia diagnosed under veno-arterial extracorporeal membrane oxygenation: a retrospective nationwide study. Intensive Care Medicine. 2018;44:1460-9. [DOI:10.1007/s00134-018-5346-y]
59. Muhammad S, Naeem A, Shaukat A, Javaid S, Alvi S. Drug-Induced Immune Thrombocytopenia From Administration of a Local Anesthetic Agent Resulting in Splenectomy. Cureus. 2020;12(5). [DOI:10.7759/cureus.8293]
60. Narayanan PK, Henry S, Li N. Drug-induced thrombocytopenia: mechanisms and relevance in preclinical safety assessment. Current Opinion in Toxicology. 2019;17:23-30. [DOI:10.1016/j.cotox.2019.10.002]
61. Marini I, Uzun G, Jamal K, Bakchoul T. Treatment of drug-induced immune thrombocytopenias. Haematologica. 2022;107(6):1264. [DOI:10.3324/haematol.2021.279484]
62. Sun S, Urbanus RT, Ten Cate H, de Groot PG, de Laat B, Heemskerk JW, et al. Platelet activation mechanisms and consequences of immune thrombocytopenia. Cells. 2021;10(12):3386. [DOI:10.3390/cells10123386]
63. Sandler GS. Alloimmune refractoriness to platelet transfusions. Current Opinion in Hematology. 1997;4(6):470-3. [DOI:10.1097/00062752-199704060-00020]
64. Pavenski K, Freedman J, Semple J. HLA alloimmunization against platelet transfusions: pathophysiology, significance, prevention and management. Tissue antigens. 2012;79(4):237-45. [DOI:10.1111/j.1399-0039.2012.01852.x]
65. Saris A, Pavenski K. Human leukocyte antigen alloimmunization and alloimmune platelet refractoriness. Transfusion Medicine Reviews. 2020;34(4):250-7. [DOI:10.1016/j.tmrv.2020.09.010]
66. Bonstein L, Stemer G, Dann EJ, Zuckerman T, Fineman R, Haddad N. Alloimmune platelet transfusion refractoriness circumvented by allogeneic stem cell transplantation. Transfusion. 2013;53(5):1019-23. [DOI:10.1111/j.1537-2995.2012.03855.x]
67. Couvidou A, Angénieux C, Ruch L, Mangin PH, Gachet C, Maître B. Marginal zone B cells are responsible for the production of alloantibodies following platelet transfusion in mice. Blood Advances. 2023;7(8):1356-65. [DOI:10.1182/bloodadvances.2022008411]
68. Vilches M, Nieto A, editors. Analysis of pregnancy-induced anti-HLA antibodies using Luminex platform. Transplantation proceedings; 2015: Elsevier. [DOI:10.1016/j.transproceed.2015.09.032]
69. Vrbensky JR, Moore JE, Arnold DM, Smith JW, Kelton JG, Nazy I. The sensitivity and specificity of platelet autoantibody testing in immune thrombocytopenia: a systematic review and meta‐analysis of a diagnostic test. Journal of Thrombosis and Haemostasis. 2019;17(5):787-94. [DOI:10.1111/jth.14419]
70. Garraud O, Cognasse F, Moncharmont P. Immunological features in the process of blood platelet-induced alloimmunisation, with a focus on platelet component transfusion. Diseases. 2019;7(1):7. [DOI:10.3390/diseases7010007]
71. Cognasse F, Hally K, Fauteux-Daniel S, Eyraud M-A, Arthaud C-A, Fagan J, et al. Effects and side effects of platelet transfusion. Hämostaseologie. 2021;41(02):128-35. [DOI:10.1055/a-1347-6551]
72. Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology. 2002;46(4):1019-27. [DOI:10.1002/art.10187]
73. Ghanima W, Godeau B, Cines DB, Bussel JB. How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. Blood, The Journal of the American Society of Hematology. 2012;120(5):960-9. [DOI:10.1182/blood-2011-12-309153]
74. Bussel J, Cooper N, Boccia R, Zaja F, Newland A. Immune thrombocytopenia. Expert Review of Hematology. 2021;14(11):1013-25. [DOI:10.1080/17474086.2021.1995347]
75. Townsley DM, Desmond R, Dunbar CE, Young NS. Pathophysiology and management of thrombocytopenia in bone marrow failure: possible clinical applications of TPO receptor agonists in aplastic anemia and myelodysplastic syndromes. International journal of hematology. 2013;98:48-55. [DOI:10.1007/s12185-013-1352-6]
76. Stanworth SJ, Estcourt LJ, Powter G, Kahan BC, Dyer C, Choo L, et al. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. New England Journal of Medicine. 2013;368(19):1771-80. [DOI:10.1056/NEJMoa1212772]
77. Kiefel V. Differential Diagnosis of Acute Thrombocytopenia. FUNDAMENTAL AND CLINICAL CARDIOLOGY. 2000;39:17-42.
78. Nurden AT, Pillois X, Wilcox DA, editors. Glanzmann thrombasthenia: state of the art and future directions. Seminars in thrombosis and hemostasis; 2013: Thieme Medical Publishers. [DOI:10.1055/s-0033-1353393]
79. Nurden A, Freson K, Seligsohn U. Inherited platelet disorders. Haemophilia. 2012;18:154-60. [DOI:10.1111/j.1365-2516.2012.02856.x]
80. Nurden AT. Acquired Glanzmann thrombasthenia: from antibodies to anti-platelet drugs. Blood Reviews. 2019;36:10-22. [DOI:10.1016/j.blre.2019.03.004]
81. Schiffer C. Diagnosis and management of refractoriness to platelet transfusion. Blood reviews. 2001;15(4):175-80. [DOI:10.1054/blre.2001.0164]
82. Jiao S, Zhao L, Zhou H. Detect and characterize platelet-reactive antibodies in patients who were refractory to platelet transfusions. Chinese Journal of Blood Transfusion. 1988.
83. Chiueh T-S, Wang H-Y, Wu M-H, Hsueh Y-S, Chen H-C. Evaluation of Platelet Alloimmunization by Filtration Enzyme-Linked Immunosorbent Assay. Diagnostics. 2023;13(10):1704. [DOI:10.3390/diagnostics13101704]
84. Pavenski K, Rebulla P, Duquesnoy R, Saw CL, Slichter SJ, Tanael S, et al. Efficacy of HLA‐matched platelet transfusions for patients with hypoproliferative thrombocytopenia: a systematic review. Transfusion. 2013;53(10):2230-42. [DOI:10.1111/trf.12175]
85. Kopko PM, Warner P, Kresie L, Pancoska C. Methods for the selection of platelet products for alloimmune‐refractory patients. Transfusion. 2015;55(2):235-44. [DOI:10.1111/trf.12921]
86. Moncharmont P. Platelet component transfusion and alloimmunization: where do we stand? Transfusion Clinique et Biologique. 2018;25(3):172-8. [DOI:10.1016/j.tracli.2018.01.003]
87. Bub CB, Martinelli BM, Avelino TM, Gonçalez AC, Barjas-Castro MdL, Castro V. Platelet antibody detection by flow cytometry: an effective method to evaluate and give transfusional support in platelet refractoriness. Revista brasileira de hematología e hemoterapia. 2013;35(4):252-5. [DOI:10.5581/1516-8484.20130062]
88. Gras C, Schulze K, Goudeva L, Guzman CA, Blasczyk R, Figueiredo C. HLA-universal platelet transfusions prevent platelet refractoriness in a mouse model. Human gene therapy. 2013;24(12):1018-28. [DOI:10.1089/hum.2013.074]
89. Sazama K, DeChristopher PJ, Dodd R, Harrison CR, Shulman IA, Cooper ES, et al. Practice parameter for the recognition, management, and prevention of adverse consequences of blood transfusion. Archives of pathology & laboratory medicine. 2000;124(1):61-70. [DOI:10.5858/2000-124-0061-PPFTRM]
90. Pavenski K, Webert KE, Goldman M. Consequences of transfusion of platelet antibody: a case report and literature review. Transfusion. 2008;48(9):1981-9. [DOI:10.1111/j.1537-2995.2008.01796.x]
91. Godeau B, Porcher R, Fain O, Lefrère F, Fenaux P, Cheze S, et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood, The Journal of the American Society of Hematology. 2008;112(4):999-1004. [DOI:10.1182/blood-2008-01-131029]
92. Lazarus AH, Freedman J, Semple JW. Intravenous immunoglobulin and anti-D in idiopathic thrombocytopenic purpura (ITP): mechanisms of action. Transfusion science. 1998;19(3):289-94. [DOI:10.1016/S0955-3886(98)00043-5]
93. Fasano RM, Josephson CD. Platelet transfusion goals in oncology patients. Hematology 2014, the American Society of Hematology Education Program Book. 2015;2015(1):462-70. [DOI:10.1182/asheducation-2015.1.462]
94. Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood. 2004;104(9):2623-34. [DOI:10.1182/blood-2004-03-1168]
95. Kumawat V, Sharma RR, Malhotra P, Marwaha N. Prevalence of risk factors for platelet transfusion refractoriness in multitransfused hemato-oncological patients at tertiary care center in North India. Asian journal of transfusion science. 2015;9(1):61-4. [DOI:10.4103/0973-6247.150953]
96. Garraud O, Cognasse F, Tissot J-D, Chavarin P, Laperche S, Morel P, et al. Improving platelet transfusion safety: biomedical and technical considerations. Blood transfusion. 2015;14(2):109.
97. Yankee R, Grumet F, Rogentine G. Platelet transfusion therapy: The selection of compatible platelet donors for refractory patients by lymphocyte HL-A typing. New England Journal of Medicine. 1969;281(22):1208-12. [DOI:10.1056/NEJM196911272812202]
98. Juskewitch JE, Norgan AP, De Goey SR, Duellman PM, Wakefield LL, Gandhi MJ, et al. How do I… manage the platelet transfusion-refractory patient? Transfusion. 2017;57(12):2828-35. [DOI:10.1111/trf.14316]
99. Slichter SJ, Fish D, Abrams VK, Gaur L, Nelson K, Bolgiano D. Evaluation of different methods of leukoreduction of donor platelets to prevent alloimmune platelet refractoriness and induce tolerance in a canine transfusion model. Blood. 2005;105(2):847-54. [DOI:10.1182/blood-2003-08-2942]
100. Tasaki T, Fujii K, Gotoh K, Satoh S, Takadate J, Sasaki S, et al. Pre-transfusion screening for platelet-reactive antibodies. Transfusion and apheresis science. 2005;33(2):157-64. [DOI:10.1016/j.transci.2005.04.008]
101. Estcourt L, Birchall J, Allard S, Bassey S, Hersey P, Kerr J, et al. Guidelines for the use of platelet transfusions. British journal of haematology. 2016;176(3). [DOI:10.1111/bjh.14423]
102. Kaufman RM, Djulbegovic B, Gernsheimer T, Kleinman S, Tinmouth AT, Capocelli KE, et al. Platelet transfusion: a clinical practice guideline from the AABB. Annals of internal medicine. 2015;162(3):205-13. [DOI:10.7326/M14-1589]
103. Ness PM, Campbell-Lee SA. Single donor versus pooled random donor platelet concentrates. Current opinion in hematology. 2001;8(6):392-6. [DOI:10.1097/00062752-200111000-00013]
104. Chu Y-H, Rose WN, Nawrot W, Raife TJ. Pooled platelet concentrates provide a small benefit over single-donor platelets for patients with platelet refractoriness of any etiology. Journal of International Medical Research. 2021;49(5):03000605211016748. [DOI:10.1177/03000605211016748]
105. Song X, Qi J, Fang K, Li X, Han Y. A meta-analysis of risk factors associated with platelet transfusion refractoriness. International Journal of Hematology. 2023;117(6):863-75. [DOI:10.1007/s12185-023-03557-3]
106. Sharma AD, Sreeram G, Erb T, Grocott HP, Slaughter TF. Leukocyte-reduced blood transfusions: perioperative indications, adverse effects, and cost analysis. Anesthesia & Analgesia. 2000;90(6):1315-23. [DOI:10.1097/00000539-200006000-00010]
107. Chambers L, Kruskall M, Pacini D, Donovan L. Febrile reactions after platelet transfusion: the effect of single versus multiple donors. Transfusion. 1990;30(3):219-21. [DOI:10.1046/j.1537-2995.1990.30390194340.x]
108. Prak ETL. Approach to the Platelet Refractory Patient. Handbook of Transfusion Medicine: Elsevier; 2001. p. 209-19. [DOI:10.1016/B978-012348775-9/50075-2]
109. Rebulla P, Morelati F, Revelli N, Villa MA, Paccapelo C, Nocco A, et al. Outcomes of an automated procedure for the selection of effective platelets for patients refractory to random donors based on cross‐matching locally available platelet products. British journal of haematology. 2004;125(1):83-9. [DOI:10.1111/j.1365-2141.2004.04865.x]
110. van Marwijk Kooy M, van Prooijen HC, Moes M, Bosma-Stants I, Akkerman J-WN. Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: a prospective, randomized trial. Blood. 1991;77(1):201-5. https://doi.org/10.1182/blood.V77.1.201.bloodjournal771201 [DOI:10.1182/blood.V77.1.201.201]
111. Slichter SJ, Davis K, Enright H, Braine H, Gernsheimer T, Kao K-J, et al. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood. 2005;105(10):4106-14. [DOI:10.1182/blood-2003-08-2724]
112. Cid J. Prevention of transfusion‐associated graft‐versus‐host disease with pathogen‐reduced platelets with amotosalen and ultraviolet A light: a review. Vox Sanguinis. 2017;112(7):607-13. [DOI:10.1111/vox.12558]
113. Slichter SJ, Bolgiano D, Kao K-J, Kickler TS, McFarland J, McCullough J, et al. Persistence of lymphocytotoxic antibodies in patients in the trial to reduce alloimmunization to platelets: implications for using modified blood products. Transfusion medicine reviews. 2011;25(2):102-10. [DOI:10.1016/j.tmrv.2010.11.002]
114. Akuta K, Fukushima K, Nakata K, Hayashi S, Toda J, Shingai Y, et al. Autoimmune-mediated thrombocytopenia after allogeneic hematopoietic stem cell transplantation: Significance of detecting reticulated platelets and glycoprotein-specific platelet autoantibodies. International Journal of Hematology. 2022:1-7. [DOI:10.1007/s12185-021-03272-x]
115. Chapman JM, Wendt L, Knudson CM. Comparison of platelet antibody screen, crossmatching and HLA antibody testing in patients refractory to platelet transfusions. Transfusion and Apheresis Science. 2023;62(3):103622. [DOI:10.1016/j.transci.2022.103622]
116. Kueht ML, Dongur LP, Mujtaba MA, Cusick MF. Antibody therapeutics as interfering agents in flow cytometry crossmatch for organ transplantation. Journal of Personalized Medicine. 2023;13(6):1005. [DOI:10.3390/jpm13061005]
117. Marsh SG, Albert E, Bodmer W, Bontrop R, Dupont B, Erlich H, et al. Nomenclature for factors of the HLA system, 2010. Tissue antigens. 2010;75(4):291. [DOI:10.1111/j.1399-0039.2010.01466.x]
118. Mathur A, Thapa S, Jagannathan L. Evaluation of crossmatch techniques for deceased donor transplant program-Need of the hour. Global Journal of Transfusion Medicine. 2020;5(2):155-8. [DOI:10.4103/GJTM.GJTM_20_20]
119. Kekomäki R. Use of HLA‐and HPA‐matched platelets in alloimmunized patients. Vox sanguinis. 1998;74(S2):359-63. [DOI:10.1111/j.1423-0410.1998.tb05443.x]
120. Feng M, Liu D, Shen W, Wang J, Guo Z, Zhang X, et al. Establishment of an HPA‐1‐to‐16‐typed platelet donor registry in China. Transfusion medicine. 2006;16(5):369-74. [DOI:10.1111/j.1365-3148.2006.00687.x]
121. Verran DG, J. Bennett, JAG Lown, WN Erber, J. HPA-1, 3, 5 genotyping to establish a typed platelet donor panel. Pathology. 2000;32(2):89-93. [DOI:10.1080/003130200104295]
122. Reynolds SJ. Evaluation of the provision of crossmatch compatible platelets for haematology patients who have acquired non-immune refractoriness: Manchester Metropolitan University; 2022.
123. Chugh S, Darvish-Kazem S, Lim W, Crowther MA, Ghanima W, Wang G, et al. Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis. The Lancet Haematology. 2015;2(2):e75-e81. [DOI:10.1016/S2352-3026(15)00003-4]
124. Neunert CE. Management of newly diagnosed immune thrombocytopenia: can we change outcomes? Blood advances. 2017;1(24):2295-301. [DOI:10.1182/bloodadvances.2017009860]
125. Neunert C, Terrell DR, Arnold DM, Buchanan G, Cines DB, Cooper N, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood advances. 2019;3(23):3829-66. [DOI:10.1182/bloodadvances.2019000966]
126. Ortel TL, Neumann I, Ageno W, Beyth R, Clark NP, Cuker A, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood advances. 2020;4(19):4693-738. [DOI:10.1182/bloodadvances.2020001830]
127. Hod E, Schwartz J. Platelet transfusion refractoriness. British journal of haematology. 2008;142(3):348-60. [DOI:10.1111/j.1365-2141.2008.07189.x]
128. Kuter DJ. Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia. Annual review of medicine. 2009;60(1):193-206. [DOI:10.1146/annurev.med.60.042307.181154]
129. Makar RS, Zhukov OS, Sahud MA, Kuter DJ. Thrombopoietin levels in patients with disorders of platelet production: diagnostic potential and utility in predicting response to TPO receptor agonists. American Journal of Hematology. 2013;88(12):1041-4. [DOI:10.1002/ajh.23562]
130. Bussel J, Kulasekararaj A, Cooper N, Verma A, Steidl U, Semple JW, et al., editors. Mechanisms and therapeutic prospects of thrombopoietin receptor agonists. Seminars in hematology; 2019: Elsevier. [DOI:10.1053/j.seminhematol.2019.09.001]
131. Kuter DJ. The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag. Blood Reviews. 2022;53:100909. [DOI:10.1016/j.blre.2021.100909]
132. Kanzler P, Mahoney A, Leitner G, Witt V, Maurer-Spurej E. Microparticle detection to guide platelet management for the reduction of platelet refractoriness in children-a study proposal. Transfusion and Apheresis Science. 2017;56(1):39-44. [DOI:10.1016/j.transci.2016.12.016]
133. Jimenez-Marco T, Castrillo A, Hierro-Riu F, Vicente V, Rivera J. Frozen and cold-stored platelets: reconsidered platelet products. Platelets. 2022;33(1):27-34. [DOI:10.1080/09537104.2021.1967917]
134. Navarro-Núñez L, Langan SA, Nash GB, Watson SP. The physiological and pathophysiological roles of platelet CLEC-2. Thrombosis and haemostasis. 2013;109(06):991-8. [DOI:10.1160/TH13-01-0060]
135. Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood, The Journal of the American Society of Hematology. 2009;113(11):2386-93. [DOI:10.1182/blood-2008-07-162503]
136. Nishimoto T, Satoh T, Takeuchi T, Ikeda Y, Kuwana M. Critical role of CD4+ CD25+ regulatory T cells in preventing murine autoantibody-mediated thrombocytopenia. Experimental hematology. 2012;40(4):279-89. [DOI:10.1016/j.exphem.2012.01.001]
137. Amini L, Kaeda J, Fritsche E, Roemhild A, Kaiser D, Reinke P. Clinical adoptive regulatory T Cell therapy: State of the art, challenges, and prospective. Frontiers in Cell and Developmental Biology. 2023;10:1081644. [DOI:10.3389/fcell.2022.1081644]
Add your comments about this article : Your username or Email:
CAPTCHA
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2025 All Rights Reserved | Iranian Journal of Blood and Cancer

Designed & Developed by : Yektaweb